Information från ABG Sundal Collier

Här finner du information kring börsens mindre och medelstora bolag. Avsändare är ABG Sundal Collier, innehållet är inte skapat av placera.nu:s redaktion.

« Tillbaka

Isofol Medical - Clinical momentum builds ahead of Phase 2

15 november 2026

<a id="bm-comp-56d24755-c9d0-4f37-8144-ae37bdb420f2" name="bm-comp-56d24755-c9d0-4f37-8144-ae37bdb420f2" class="BMCustomAnchor"></a><table><tr><td bm-component-id="56d24755-c9d0-4f37-8144-ae37bdb420f2" style="vertical-align: top; width:100.000000%;"><ul><li>Strong early efficacy signals</li><li>Solid cost control</li><li><p>Fair value range lifted to SEK 0.1-11.0/sh (SEK 0.1-10.5/sh)</p></li></ul></td></tr></table><a id="bm-comp-77a8f2b7-7494-4c8f-b38a-80b412595d25" name="bm-comp-77a8f2b7-7494-4c8f-b38a-80b412595d25" class="BMCustomAnchor"></a><table><tr><td bm-component-id="77a8f2b7-7494-4c8f-b38a-80b412595d25" style="vertical-align: top; width:100.000000%;"><h3 class="bm-h3">Strong early efficacy signals</h3><p>Last week, Isofol reported encouraging preliminary Phase 1b findings, with disease control in all evaluated patients, tumour shrinkage in a clear majority and reductions in tumour diameters of up to ~50%. Half of the patients became candidates for surgery with curative intent, a notable finding as surgery is usually not considered feasible in this population. Only one has experienced disease progression following an initial response and stable disease. No dose-limiting toxicities have been observed. Three patients remain to be enroled at the highest dose of 500 mg/m&#178; in Phase 1b. The randomised Phase 2 with 60 patients and broader inclusion criteria, is planned across 15-20 EU sites, alongside a parallel Japanese bridging trial with 27 patients. We now expect Phase 2 to start in early Q1'27e.</p><h3 class="bm-h3">Solid cost control</h3><p>For Q3, opex was below our forecast at SEK 13m (vs. ABGSCe at SEK 16m). Beyond incorporating a SEK/USD tailwind, our main estimate revision is a roughly six-month delay vs. the timeline in our IOC, reflecting a longer recruitment period for Phase 1b. Cash and cash equiv. was SEK 98m (SEK 115m at Q2'26-end). Excl. proceeds from the TO2 warrants, Isofol expects its existing cash to fund operations for the next 12 months. As before, incl./excl. the TO2 warrants, we estimate a cash runway into '28e/late '27e, respectively.</p><h3 class="bm-h3" style="text-align:left;"><font color="#1B2634">Fair value range lifted to SEK 0.1-11.0/sh</font></h3><p style="text-align:left;">In sum, our estimate revisions, incl. lower expected dilution following the share price increase, raise our fair value range to SEK 0.1-11.0/sh (0.1-10.5/sh). The risk-weighted scenario B yields a value of SEK 2.1/sh (SEK 1.8/sh). Scenario A, which assumes clinical failure (LOA: 0%), yields SEK 0.1/sh, while scenario C, which assumes full clinical and commercial success in 1L mCRC (LOA: 100%), yields SEK 11.0/sh (SEK 10.5/sh).</p></td></tr></table>

Senaste artiklar från alla bolag

Datum Titel Bolag Typ
2026-11-19 Tempest Security - Growth returns but margins lag Tempest Sec.. Analys
2026-11-19 Coor - Restarts the M&A engine Coor Analys
2026-11-18 Eltel - CMD: Growth follows the margin repair Eltel Analys
2026-11-16 Petrolia Noco - Q3 impacted by underlift Petrolia Noco Analys
2026-11-16 Proact - CMD takeaways: Clear path to 2030 targets Proact Analys
2026-11-16 Donkey Republic - Wins 1,700-bike Karlsruhe contract Donkey Repu.. Analys
2026-11-16 Ogunsen - Back to growth with a leaner base Ogunsen Analys
2026-11-15 Isofol Medical - Clinical momentum builds ahead o... Isofol Medical Analys
2026-11-13 Clavister - Scaling up with civilian business nex... Clavister Analys
2026-11-12 Generic - Seasonality in volumes with margins hol... Generic Analys
2026-11-12 Xplora Technologies - Strong beat, but shouldn't ... Xplora Tech.. Analys
2026-11-12 Clavister - Scalability on full display Clavister Analys
2026-11-12 Generic - Softer growth but stronger earnings Generic Analys
2026-11-11 Ferronordic - The new normal Ferronordic Analys
2026-11-11 Proact - New targets include adj. EPS doubling 20... Proact Analys
2026-11-11 Ferronordic - Positive trend continues Ferronordic Analys
2026-11-10 Proact - Ahead of CMD Proact Analys
2026-11-10 G5 Entertainment - Estimates raised on lower costs G5 Entertai.. Analys
2026-11-10 Coor - Momentum building in Norway Coor Analys
2026-11-09 Generic - A broader base to grow from Generic Analys